Chemistry:Abrilumab

From HandWiki

Short description: Monoclonal antibody

Abrilumab
Monoclonal antibody
Type	?
Source	Human
Target	integrin alpha-4 beta-7
Clinical data
Other names	AMG 181
ATC code	none
Identifiers
CAS Number	1342290-43-0
ChemSpider	none
UNII	Y9UQ37XT2T
KEGG	D10540
Chemical and physical data
Formula	C₆₃₆₂H₉₈₀₆N₁₆₈₆O₂₀₁₄S₅₂
Molar mass	143803.34 g·mol⁻¹

Abrilumab (INN;^[1] development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.^[2]

This drug was developed by MedImmune.

References

↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111". WHO Drug Information 28 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf.
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Abrilumab, American Medical Association.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression: Abrilumab Adalimumab Anifrolumab^† Atorolimumab Avelumab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab^† Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab^† Ulocuplumab Varlilumab Immune activation: Ipilimumab Atezolizumab Durvalumab Nivolumab Pembrolizumab Tremelimumab^† Urelumab Other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab^§ Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab^† Daclizumab Dostarlimab^† Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Inebilizumab^† Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab^† Siplizumab Spartalizumab^† Talizumab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab
Chimeric + humanized ("-lixizu-")	Otelixizumab Sutimlimab^†

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab^† Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Bimekizumab^† Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Tildrakizumab
Veterinary ("-kivet-")	Lokivetmab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

0.00

(0 votes)

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Abrilumab&oldid=766949"